Your browser doesn't support javascript.
SARS-CoV-2 Antibodies and Associated Factors at Different Hospitalization Time Points in 192 COVID-19 Cases.
Ou, Jingyi; Tan, Mingkai; He, Haolan; Tan, Haiyan; Mai, Jiewen; Long, Yaoxiang; Jiang, Xiaowen; He, Qing; Huang, Ying; Li, Yan; Chen, Renshen; Li, Liya; Shi, Yaling; Li, Fang.
  • Ou J; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Tan M; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • He H; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Tan H; Department of Laboratory Medicine, Guangzhou Baiyun District Maternal and Child Health Hospital, Guangzhou, China.
  • Mai J; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Long Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Jiang X; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • He Q; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Huang Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Li Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Chen R; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Li L; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Shi Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Li F; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
J Appl Lab Med ; 6(5): 1133-1142, 2021 09 01.
Article in English | MEDLINE | ID: covidwho-1334229
ABSTRACT

BACKGROUND:

We launched a retrospective analysis of SARS-CoV-2 antibodies in 192 patients with COVID-19, aiming to depict the kinetic profile of SARS-CoV-2 antibodies and explore the factors related to SARS-CoV-2 antibody expression.

METHODS:

Data on 192 confirmed patients with COVID-19 between January and February 2020 was collected from the designated hospital that received patients with COVID-19 in Guangzhou, China. Moreover, a cohort of 130 suspected patients with COVID-19 and 209 healthy people were also enrolled in this study. IgM and IgG antibodies to SARS-CoV-2 were detected by the chemiluminescence immunoassay kits in different groups.

RESULTS:

A total of 192 COVID-19 cases were analyzed, of which had 81.8% anti-SARS-CoV-2 IgM detected and 93.2% anti-SARS-CoV-2 IgG detected, respectively, at the time of sampling. The kinetics of anti-SARS-CoV-2 IgM and IgG showed that, the confirmed cases had anti-SARS-CoV-2 IgM seroconversion occurred 5-10 days after the onset of the symptoms, and then IgM rose rapidly to reach a peak within around 2-3 weeks, maintaining at its peak for 1 week before its decline. While they had anti-SARS-CoV-2 IgG seroconversion simultaneously or sequentially with IgM, reaching its peak within around 3 to 4 weeks and began to decline after the fifth week. Besides, correlation analysis showed that in patients with COVID-19 the level of IgM was related to gender and disease severity (P < 0.01), and the level of IgG was related to age and disease severity (P < 0.001). The univariate analysis of relevant factors indicated that the level of IgG had a weak correlation with age (r = 0.374, P < 0.01). The level of IgM in male patients was higher than that in female patients (P < 0.001). The expression level of anti-SARS-CoV-2 IgM and IgG were positively correlated with the severity of COVID-19 and the duration of the virus in the patients.

CONCLUSION:

The findings of this study show that anti-SARS-CoV-2 IgM and IgG can be important assisting COVID-19 diagnosis, especially in the early phase of infection. Furthermore, antibody expression in patients with COVID-19 is also correlated with disease severity, age, gender, and virus clearance or continuous replication.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Language: English Journal: J Appl Lab Med Year: 2021 Document Type: Article Affiliation country: Jalm

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Male Language: English Journal: J Appl Lab Med Year: 2021 Document Type: Article Affiliation country: Jalm